ARCHIVES

FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | March 16, 2007

Download PDF Visit The Full Archive

Related Articles

AHRQ Draft Report Finds No Benefit For Biomarker Testing In Oncology

February 5, 2010

ACCC To Consider Cancer Act Changes HSA Problems

January 7, 1977

NCI Leaders, Others Defend Cancer Program Against Bailar’s Charge They Are Losing War Against Cancer

May 16, 1986

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

July 26, 2013

Vaccine and LDCT Pretreatment Can Help PDACs Become Vulnerable to Immunotherapy

June 27, 2014

Program Announcements. RAPID Program Date Change.

June 29, 2001